<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04091906</url>
  </required_header>
  <id_info>
    <org_study_id>JSPH-CTA101-PBMC</org_study_id>
    <nct_id>NCT04091906</nct_id>
  </id_info>
  <brief_title>PBMC Donation in UCAR-T Cells</brief_title>
  <official_title>Peripheral Blood Mononuclear Cell Donation Protocol for Tumor Immunotherapy Study of UCAR-T Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nanjing Bioheng Biotech Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Peripheral blood mononuclear cell donation protocol for tumor immunotherapy study of UCAR-T
      cells
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Collect blood samples</measure>
    <time_frame>Baseline</time_frame>
    <description>Collect blood samples (whole blood and PBMC) from healthy donors for the development and production of UCAR-T cells</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Collect blood samples</measure>
    <time_frame>Baseline</time_frame>
    <description>Collect blood samples (whole blood) for pre-preparation of autologous CAR-T cells, comparation with UCAR-T products, exploration of the differences in cell expansion and function between UCAR-T and autologous CAR-T, and pre-experiments in the development of various test methodologies</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Peripheral Blood Mononuclear Cell Donation</condition>
  <arm_group>
    <arm_group_label>Healthy donor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Peripheral blood mononuclear cell apheresis</intervention_name>
    <description>Peripheral blood mononuclear cell donation for tumor immunotherapy study of UCAR-T cells</description>
    <arm_group_label>Healthy donor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female aged 18-40 years, no donation reaction in the past;

          2. Weight: male ≥ 50 kg, female ≥ 45 kg, and 18.5 kg/m2 ≤ BMI ≤ 30 kg/m2;

          3. Blood pressure:

        12.0 Kpa (90 mmHg) ≤ systolic pressure﹤18.7 Kpa (140 mmHg) 8.0 Kpa (60 mmHg) ≤ diastolic
        pressure﹤12.0 Kpa (90 mmHg) Pulse pressure ≥ 4.0Kpa (30mmHg); 4) Pulse: 60/min to 100/min.
        Athletes with high endurance ≥ 50/min, with regular rhythm; 5) Temperature: 36.3-37.2℃
        (oral temperature); 6) Generally in good condition: no damage to important organs such as
        heart, lung, liver and kidney; no severe or uncontrolled infection; no history of severe
        mental disorders; 7) Clinical examination should meet the following criteria:

          1. Hemoglobinometry: male ≥ 120g/L; female ≥ 110g/L. If using copper sulfate method: male
             ≥ 1.0520, female ≥ 1.0510

          2. White blood cell (WBC) test: ≥4×109/L

          3. Alanine aminotransferase (ALT) ≤40U/L (Rate method), ≤25U/L (Reitman-Frankel method)

          4. Hepatitis B virus surface antigen (HBsAg) negative

          5. Hepatitis C virus antibody (HCV antibody) negative

          6. Human immunodeficiency virus antibody (HIV-1 and HIV-2 antibody) negative

          7. Syphilis negative

          8. Cytomegalovirus antibody (CMV antibody) negative

          9. Epstein-Barr virus antibody (EBV antibody) negative

        Exclusion Criteria:

        Donors are ineligible to donate PBMC under the following circumstances:

        1) Valetudinarian, with frequent dizziness, giddiness, tinnitus, hemophobia, fear of
        needles, faint, and Meniere's disease; 2) Sexually transmitted diseases (STDs), leprosy,
        AIDS, and HIV-1, HIV-2, CMV, EBV antibody positive; 3) History of liver diseases, HBsAg
        positive and HCV antibody positive. 1 year after the clinical cure of hepatitis A, normal
        ALT test results at 1 month interval for 3 consecutive times; 4) Relapsed allergic
        diseases, urticaria, bronchial asthma and drug allergies (Donors with simple urticaria who
        are not in acute attack are eligible to donate PBMC); 5) Pulmonary tuberculosis, renal
        tuberculosis, lymph node tuberculosis and bone tuberculosis; 6) Cardiovascular disease and
        history, various heart diseases, hypertension, hypotension, myocarditis and
        thrombophlebitis; 7) Respiratory diseases (including chronic bronchitis, emphysema,
        bronchiectasis and pulmonary insufficiency); 8) Digestive system diseases (e.g. severe
        gastric and duodenal ulcers, chronic gastroenteritis and chronic pancreatitis); 9) Urinary
        system diseases (e.g. acute and chronic nephritis, chronic urinary system infection,
        nephrotic syndrome, acute and chronic renal insufficiency, etc.); 10) Various hematological
        diseases (including anemia, leukemia, polycythemia vera and various hemorrhagic and
        coagulative diseases); 11) Endocrine diseases or metabolic disorders (e.g. hyperthyroidism,
        acromegaly, diabetes insipidus, diabetes mellitus, etc.); 12) Organic nervous system
        diseases or psychoses (e.g. encephalitis, sequelae of brain trauma, epilepsy,
        schizophrenia, hysteria, severe neurasthenia, etc.); 13) Parasitic diseases and endemic
        diseases (e.g. kala-azar, schistosomiasis, filariasis, hookworm disease, taeniasis,
        paragonimiasis, Keshan disease, Kaschin-Beck disease, etc.); 14) Malignancies and benign
        tumors affecting health; 15) History of haematological malignancies (e.g. leukaemia,
        lymphoma, myeloma), history of malignancies known to be associated with viraemic conditions
        (except for carcinoma in situ of the cervix). For other cancers, the donors should have
        fully recovered with no expectation of recurrence (i.e. cured) and the following conditions
        apply:

          1. for cancers with negligible metastatic potential (e.g. basal cell carcinoma and
             carcinoma in situ of the cervix), the donors may be accepted immediately following
             successful removal and cure

          2. for all other cancers, at least 5 years should have elapsed since completion of active
             treatment 16) Undergone resection of stomach, kidney, gallbladder, spleen, lung and
             other important organs; 17) Exposure to harmful substances or radioactive substances
             (except for clinical radiology); 18) High-risk groups susceptible to HIV infection,
             such as drug users, homosexuals and people with multiple sexual partners; 19)
             Creutzfeldt-Jakob disease (CJD), variant Creutzfeldt disease (vCJD), family history,
             and treatment with human and animal pituitary-derived substances (e.g. growth hormone,
             gonadotropin, thyrotropin, etc.). Organ transplantation recipients (including cornea,
             bone marrow, dura mater) may be exposed to bovine spongiform encephalopathy (BSE) and
             vCJD; 20) Chronic skin diseases, especially infectious, allergic and inflammatory
             systemic skin diseases (e.g. favus, generalized eczema, systemic psoriasis, etc.); 21)
             Autoimmune diseases and collagenosis (e.g. systemic lupus erythematosus,
             dermatomyositis, scleroderma, etc.); 22) Bitten by animals carrying rabies virus; 23)
             Other diseases or conditions in which donors are ineligible to donate PBMC in the
             opinion of physicians;

        Donors should be deferred for the time being under the following circumstances:

          1. Tooth extraction or other minor surgery within half a month;

          2. 3 days before or after menstruation, menstrual disorders, pregnancy, less than 6
             months after abortion, less than 1 year after delivery and lactation;

          3. Less than 1 week after the recovery of cold and acute gastroenteritis, less than 1
             month after the cure of acute urinary system infection, and less than half a year
             after the cure of pneumonia;

          4. Donors from high-risk areas of infectious diseases as prescribed by certain infectious
             diseases and epidemic prevention departments. Less than half a year after the cure of
             dysentery, less than 1 year after the cure of typhoid fever and brucellosis, history
             of malaria within 3 years;

          5. Within 2 years after blood transfusion treatment;

          6. Less than 1 year after tattoo, injuries or contaminated wounds caused by equipment
             contaminated by blood or tissue fluid;

          7. Close contact history with patients with infectious diseases: within the longest
             incubation period of the disease after the date of contact;

          8. Recipients of animal serum products: within 4 weeks after the last injection;

          9. Recipients of hepatitis B immunoglobulin (HBIG) injection: within 1 year;

        Provisions for PBMC collection after immunization:

        1) Asymptomatic donors who have recently received immunization may donate PBMC only after
        the following period of time: 2 weeks after the last immunization of measles, mumps, yellow
        fever, poliomyelitis and live attenuated hepatitis A vaccine, 4 weeks after the last
        immunization of live rubella vaccine and rabies vaccine;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jianyong Li, Ph.D.</last_name>
    <phone>025-83718836</phone>
    <email>lijianyonglm@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>the First Affiliated Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianyong Li, PhD</last_name>
      <email>lijianyonglm@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 15, 2019</study_first_submitted>
  <study_first_submitted_qc>September 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2019</study_first_posted>
  <last_update_submitted>September 15, 2019</last_update_submitted>
  <last_update_submitted_qc>September 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

